Donaldson Company (DCI) Jefferies Global Industrial Conference 2024 summary
Event summary combining transcript, slides, and related documents.
Jefferies Global Industrial Conference 2024 summary
22 Jan, 2026Strategic direction and technology leadership
Focused on technology leadership with over 2,700 active patents and a proprietary approach across all business segments.
Operates in three segments: Mobile Solutions, Industrial Solutions, and Life Sciences, with a balanced mix of original equipment and replacement parts.
Strategic growth is targeted and balanced, with recent entry and expansion in the Life Sciences market.
Maintains a global presence, manufacturing 75% of products within the region they are sold, supporting strong customer relationships.
Diversified portfolio enables resilience against market headwinds and supports long-term profitability.
Financial performance and outlook
Achieved record revenues and earnings in recent years, with mid-single-digit sales growth expected to continue.
Operating margin expanded from 13.5% to 15.4% over three years, with a target to reach high 15% in the current fiscal year.
Fiscal 2026 targets include 3–7% CAGR and an increased operating margin of 16.2%.
Strong balance sheet with net debt to EBITDA at 0.5, supporting ongoing acquisitions and cash management.
Free cash flow conversion is near 100%, with capital allocated primarily to organic/inorganic growth and dividends.
Innovation, digitalization, and market expansion
Digitization of industrial solutions, such as connected dust collectors, drives higher aftermarket sales and margin benefits.
Expansion of digital solutions to India, China, and Thailand, with simplified installation and broader compatibility.
Life Sciences segment targets cell and gene therapy markets, leveraging both organic growth and niche acquisitions.
Recent acquisitions include Purilogics (membrane-based chromatography) and Medica (hollow fiber membranes), with new products expected in coming quarters.
Proprietary solvent reclamation technology in Life Sciences enables new business opportunities and significant cost savings for customers.
Latest events from Donaldson Company
- Record sales and margin growth driven by innovation, global reach, and strategic acquisitions.DCI
47th Annual Raymond James Institutional Investor Conference4 Mar 2026 - Q2 sales up 3% to $896M, flat EPS, and $820M Facet acquisition to boost future margins.DCI
Q2 202626 Feb 2026 - Record results and strong outlook driven by aftermarket growth, technology, and disciplined capital strategy.DCI
Morgan Stanley’s 13th Annual Laguna Conference3 Feb 2026 - Life Sciences and innovation drive growth, with record margins and expanding global opportunities.DCI
The 44th Annual William Blair Growth Stock Conference1 Feb 2026 - Record Q3 sales, margin expansion, and raised EPS guidance highlight robust growth.DCI
Q3 202431 Jan 2026 - Proprietary technology, global expansion, and strategic investments drive growth and resilience.DCI
Stifel 2024 Cross Sector Insight Conference31 Jan 2026 - Record sales, margin expansion, and robust Aftermarket growth drive FY24 earnings higher.DCI
Q4 202423 Jan 2026 - Technology-driven growth, M&A, and aftermarket strength fuel margin and share gains.DCI
Morgan Stanley‘s 12th Annual Laguna Conference 202420 Jan 2026 - Record sales, margin growth, and Life Sciences expansion drive future-focused strategy.DCI
CL King's 22nd Annual Best Ideas Conference 202420 Jan 2026